Neurotrope, Inc. (NTRP)
Stock Price:
$0.941 USD
-0.109 (-10.38%)
Updated December 1, 4:00 PM EST - Market closed
After-hours: $1.070 +0.129 (13.71%) Dec 1, 6:44 PM
Key Info
| Market Cap |
22.39M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-12.35M |
| Shares Out |
23.79M |
| EPS (ttm) |
-0.64 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 1 |
| Last Price |
$0.941 |
| Previous Close |
$1.050 |
| Change ($) |
-0.109 |
| Change (%) |
-10.38% |
| Day's Open |
1.040 |
| Day's Range |
0.915 - 1.040 |
| Day's Volume |
500,213 |
| 52-Week Range |
0.713 - 1.470 |
More Stats
| Market Cap |
22.39M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
23.79M |
| Float |
n/a |
| EPS (basic) |
-0.64 |
| EPS (diluted) |
-0.64 |
| FCF / Share |
-0.35 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
46,336 |
| Short Ratio |
0.19 |
| Short % of Float |
n/a |
| Beta |
2.26 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
0.90 |
| Revenue |
n/a |
| Operating Income |
-10.88M |
| Net Income |
-12.35M |
| Free Cash Flow |
-8.42M |
| Net Cash |
27.00M |
| Net Cash / Share |
1.13 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-27.73% |
| ROE |
-52.59% |
| ROIC |
-11,044.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
1.00
Current: $0.941
High
1.00
Target: 1.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | - | - | - | - | - | - | - |
| Operating Income | -15.51 | -11.15 | -12.70 | -12.93 | -9.45 | -9.27 | -7.59 |
| Net Income | -15.13 | -11.02 | -12.62 | -12.92 | -9.44 | -9.25 | -7.59 |
| Shares Outstanding | 12.99 | 8.05 | 7.71 | 2.27 | 0.84 | 0.69 | 0.68 |
| Earnings Per Share | -1.16 | -1.37 | -1.64 | -5.69 | -11.64 | -15.68 | -12.80 |
| Operating Cash Flow | -11.89 | -7.70 | -10.99 | -7.38 | -10.32 | -7.15 | -5.53 |
| Capital Expenditures | -0.01 | - | - | - | -0.01 | -0.05 | - |
| Free Cash Flow | -11.89 | -7.70 | -10.99 | -7.38 | -10.33 | -7.21 | -5.53 |
| Cash & Equivalents | 17.38 | 28.85 | 16.11 | 25.77 | 11.23 | 8.01 | 15.21 |
| Total Debt | - | - | - | - | 0.01 | - | - |
| Net Cash / Debt | 17.38 | 28.85 | 16.11 | 25.77 | 11.22 | 8.01 | 15.21 |
| Assets | 17.90 | 29.48 | 16.44 | 25.97 | 12.78 | 8.16 | 15.30 |
| Liabilities | 0.48 | 2.96 | 1.56 | 2.36 | 12.81 | 19.81 | 20.35 |
| Book Value | 17.42 | 26.52 | 14.89 | 23.60 | -0.02 | -11.65 | -5.05 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Neurotrope, Inc. |
| Country |
United States |
| Employees |
5 |
| CEO |
Charles S. Ryan |
Stock Information
| Ticker Symbol |
NTRP |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: NTRP |
Description
Neurotrope, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.